On seekingalpha: (New users cannot put links)
“Although the negative symptom reduction did not reach statistical significance at Week 5, it demonstrated significance at Week 4.” doesn’t sound too promising, but I want to see a clinical trial over more than only 5 weeks!
Looks like it’s a bust for negatives then…
There are hopes for Nuplazid instead:
" A further competitive threat to the future of roluperidone is Acadia Pharmaceuticals’ Nuplazid (pimavanserin tartrate) , which is being developed as an adjunctive therapy to target the negative symptoms of schizophrenia and is anticipated to launch in the US in Q4 2025. Unlike roluperidone, Nuplazid can be used in conjunction with antipsychotic therapies either long-term or during relapses, when positive symptoms of schizophrenia return."
It’s not ethical to compare it vs placebo for more than 6 weeks… Imagine you are having an episode and I give you a placebo just for a trial for more than 6 weeks, potentially damaging your brain, is the trial justified?
Me too. I wanna see that med tested for at least 2 years before release
Sounds reasonable. However, what about giving KarXT as an adjunctive to a stable antipsychotic medication and see if it improves negative and cognitive symptoms? According to the pipeline of Karuna, they are both testing it as monotherapy and adjunctive.
It looks like Ulotaront is more for non-cognitive negative symptoms, right? Also, the reduction in the PANSS score seems to be less than with KarXT.
Yes, ulotaront treats more variety of symptoms but less effective for each
The effect size of ulotarant, that includes PANSS, is actually quite good in trials so far. The effect size is ok in a short term trial but may be better in a long term trial.